Private Placement and Retail Offering successfully placed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Zelluna ASA: Private Placement and Retail Offering successfully placed

• Private Placement and Retail Offering successfully completed, raising gross proceeds of approximately NOK 58.2 million
• Financing intended to strengthen Zelluna's position as the Company approaches initial clinical data and enhance financial flexibility to pursue future strategic opportunities
• Advancing ZI-MA4-1, the world's first MAGE-A4-targeting off-the-shelf TCR-NK therapy in clinical development
• On track for initial clinical data to emerge from mid-2026

18 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the “Company”) on 17 June 2026 regarding a contemplated private placement of new ordinary shares (the “Private Placement”) and a retail offering of new ordinary shares facilitated through Nordnet Bank AB (the “Retail Offering” and, together with the Private Placement, the “Offerings”).

The Company is pleased to announce that the Private Placement has been successfully placed, raising gross proceeds of approximately NOK 55 million through the allocation of 2 972 973 new shares (the “Private Placement Shares”), each at a subscription price of NOK 18.50 per share (the “Offer Price”).

The Retail Offering has also been successfully placed, raising gross proceeds of approximately NOK 3.2 million through the allocation of 170 985 new shares at the Offer Price (the “Retail Offer Shares” and, together with the Private Placement Shares, the “Offer Shares”).

"We are grateful for the confidence and support shown by both existing and new investors. This financing strengthens Zelluna's position as we advance ZI-MA4-1, continue to expand the potential of our TCR-NK platform and approach anticipated initial clinical data from mid-2026. Our team remains focused on disciplined execution and on translating the promise of our science into new treatment options for patients with solid cancers," said Namir Hassan, Chief Executive Officer of Zelluna ASA.

Schreibe Deinen Kommentar